Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Abramson on TRANSCEND on JCAR017 Therapy in NHL

June 19th 2017

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

JCAR017 Impresses in Updated DLBCL Data

June 17th 2017

Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Cheah on Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma

June 17th 2017

Chan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.

Dr. Fama on GBV-C Infection and Risk of Lymphoma

June 17th 2017

Angelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.

Pembrolizumab Plus Rituximab Promising in Follicular Lymphoma

June 17th 2017

Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.

Copanlisib Lymphoma Data Updated as FDA Considers Approval

June 17th 2017

Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.

Obinutuzumab Benefit in Frontline Follicular Lymphoma Sustained With Longer Follow-Up

June 17th 2017

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

BGB-3111 Plus Obinutuzumab Effective in CLL and Follicular Lymphoma

June 17th 2017

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

Avelumab Active in Hodgkin Lymphoma

June 16th 2017

Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.

Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

June 16th 2017

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin Lymphoma

June 16th 2017

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma.

Expert Discusses Latest Nivolumab Data in Hodgkin Lymphoma

June 15th 2017

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

Pembrolizumab Active in Relapsed Mediastinal Large B-Cell Lymphoma

June 15th 2017

Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.

Attacking FLT3 Mutations Yields First Targeted Therapy in AML

June 15th 2017

Although FLT3 mutations are well established as a prognostic marker in patients with AML, efforts to target the aberration therapeutically were underway for more than 15 years before yielding success.

Novel Regimens Explored for Rare DLBCL Subtypes

June 15th 2017

Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.

Expert Discusses Ibrutinib/Venetoclax Combo in MCL

June 15th 2017

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

Tisagenlecleucel-T Highly Active, With Durable Responses in DLBCL

June 14th 2017

Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Batlevi on Safety With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

June 14th 2017

Connie Batlevi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety results of a phase I study evaluating the combination of ibrutinib (Imbruvica) and buparlisib in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Kahl on ADCT-402 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 14th 2017

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma

June 14th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).